Abstract | BACKGROUND: METHODS: A total of 625 patients with ischemic stroke were randomized to receive either enlimomab (n = 317) or placebo (n = 308) within 6 hours of stroke onset. Treatment was given over 5 days. Patients were evaluated at baseline and on days 5 and 90 after initiation of treatment; long-term assessments were carried out after 6 and 12 months. The primary efficacy endpoint was the response to therapy at 90 days on the Modified Rankin Scale; other endpoints included Barthel Index (BI) and NIH Stroke Scale and survival. RESULTS: At day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004). Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever. Patients experiencing fever were more likely to have a poor outcome or die. CONCLUSIONS:
|
Authors | Enlimomab Acute Stroke Trial Investigators |
Journal | Neurology
(Neurology)
Vol. 57
Issue 8
Pg. 1428-34
(Oct 23 2001)
ISSN: 0028-3878 [Print] United States |
PMID | 11673584
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Intercellular Adhesion Molecule-1
|
Topics |
- Acute Disease
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Brain Ischemia
(mortality, therapy)
- Disease-Free Survival
- Female
- Humans
- Intercellular Adhesion Molecule-1
(immunology)
- Male
- Middle Aged
- Stroke
(mortality, therapy)
|